SCHEMBL31486233

SCHEMBL31486233

CC[C@H]1C[C@@H](C(=O)O)n2c1cnc(NCc1cc(C)cc(C)c1)c2=O

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.34
RPS6KB1 P23443 1/20 0.33
ADORA3 P0DMS8 1/20 0.32
NR3C1 P04150 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31565045 0.89 MAPK14 (0.39) MAPK14ADORA3
SCHEMBL31486477 0.81 MCHR1 (0.38) MAPK14ADORA3
SCHEMBL31486384 0.80 MAPK14 (0.35) MAPK14RPS6KB1POLB
SCHEMBL31486436 0.80 F7 (0.34) RPS6KB1NR3C1
SCHEMBL31486324 0.80 RAB9A (0.33)
SCHEMBL31486452 0.76 RPS6KB1 (0.33) MAPK14RPS6KB1POLB
SCHEMBL31486469 0.75 MAPK14 (0.40) MAPK14ADORA3
SCHEMBL31486546 0.74 RPS6KB1 (0.39) MAPK14RPS6KB1
SCHEMBL31486305 0.73 MAPK14 (0.37) MAPK14
SCHEMBL31486510 0.68 ALDH1A1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122225-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-04-17 US disclosed
WO-2025076476-A2 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122225-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, SPINT2, SERPINB1 MAPK14 2151/4885RPS6KB1 2675/4885ADORA3 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.